APRE — Aprea Therapeutics Income Statement
0.000.00%
- $21.72m
- -$9.34m
- $0.58m
- 25
- 24
- 48
- 23
Annual income statement for Aprea Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0.583 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 29.5 | 52.8 | 37.4 | 113 | 16.1 |
Operating Profit | -29.5 | -52.8 | -37.4 | -113 | -15.5 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -28.1 | -53.5 | -37.1 | -113 | -14.3 |
Net Income After Taxes | -28.1 | -53.5 | -37.1 | -113 | -14.3 |
Net Income Before Extraordinary Items | |||||
Net Income | -28.1 | -53.5 | -37.1 | -113 | -14.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -28.1 | -53.5 | -37.1 | -113 | -14.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -26.7 | -50.6 | -34.9 | -22.1 | -3.95 |